Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: Mechanisms and therapeutic perspectives

Immunological Reviews

Volumn 222, Issue 1, 2008, Pages 180-191

  Rodríguez, Paulo C ^a   Ochoa, Augusto C ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arginase; Myeloid derived suppressor cells; T cell function

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; ARGINASE 1; ARGININE; CD3 ANTIGEN; ENZYME INHIBITOR; INDOLEAMINE 2,3 DIOXYGENASE; NITROGEN OXIDE; NOMEGA HYDROXY NOR ARGININE; ORNITHINE; PROLINE; T LYMPHOCYTE RECEPTOR; TRYPTOPHAN; UNCLASSIFIED DRUG; UREA;

AMINO ACID METABOLISM; APOPTOSIS; BONE MARROW CELL; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL CYCLE ARREST; CELL DIVISION; CELL PROLIFERATION; COLON CANCER; DENDRITIC CELL; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME METABOLISM; HEAD AND NECK TUMOR; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; KIDNEY CARCINOMA; LYMPHOCYTE FUNCTION; MELANOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE; TREATMENT OUTCOME; UPREGULATION; UTERINE CERVIX CANCER;

ANIMALS; ANTIGENS, CD3; ARGINASE; ARGININE; ENZYME INDUCTION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; MICE; MODELS, IMMUNOLOGICAL; MYELOID CELLS; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 41149148269     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2008.00608.x     Document Type: Review

References (137)

1. Miescher S, Whiteside TL, Carrel S, von F V. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol 1986 136 : 1899 1907.
2. Miescher S, Stoeck M, Qiao L, Barras C, Barrelet L, von Fliedner V. Preferential clonogenic deficit of CD8-positive T-lymphocytes infiltrating human solid tumors. Cancer Res 1988 48 : 6992 6998.
3. Whiteside TL, Miescher S, Moretta L, von Fliedner V. Cloning and proliferating precursor frequencies of tumor-infiltrating lymphocytes from human solid tumors. Transplant Proc 1988 20 : 342 343.
4. Whiteside TL, Rabinowich H. The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol Immunother 1998 46 : 175 184.
5. Hellstrom I, Sjogren HO, Warner G, Hellstrom KE. Blocking of cell-mediated tumor immunity by sera from patients with growing neoplasms. Int J Cancer 1971 7 : 226 237.
6. Hellstrom I, Sjogren HO, Warner G, Hellstrom KE. Blocking of cell-mediated tumor immunity by sera from patients with growing neoplasms. Int J Cancer 1971 7 : 226 237.
7. Hellstrom KE, Hellstrom I, Nelson K. Antigen-specific suppressor ("blocking") factors in tumor immunity. Biomembranes 1983 11 : 365 388.
8. Varesio L, Giovarelli M, Landolfo S, Forni G. Suppression of proliferative response and lymphokine production during the progression of a spontaneous tumor. Cancer Res 1979 39 : 4983 4988.
9. Miescher S, Whiteside TL, Carrel S, von Fliedner V. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol 1986 136 : 1899 1907.
10. Miescher S, Stoeck M, Qiao L, Barras C, Barrelet L, von Fliedner V. Preferential clonogenic deficit of CD8-positive T-lymphocytes infiltrating human solid tumors. Cancer Res 1988 48 : 6992 6998.
11. Whiteside TL, Miescher S, Moretta L, von Fliedner V. Cloning and proliferating precursor frequencies of tumor-infiltrating lymphocytes from human solid tumors. Transplant Proc 1988 20 : 342 343.
12. Whiteside TL, Rabinowich H. The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol Immunother 1998 46 : 175 184.
13. Gattinoni L, Powell DJ Jr., Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006 6 : 383 393.
14. Stevenson FK. Update on cancer vaccines. Curr Opin Oncol 2005 17 : 573 577.
15. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007 25 : 267 296.
16. Klausner RD, Lippincott-Schwartz J, Bonifacino JS. The T cell antigen receptor: insights into organelle biology. Annu Rev Cell Biol 1990 6 : 403 431.
17. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999 5 : 1365 1369.
18. Dong H, Zhu G, Tamada K, Flies DB, van Deursen JM, Chen L. B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity 2004 20 : 327 336.
19. Kryczek I, et al. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol 2006 177 : 40 44.
20. Kryczek I, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006 203 : 871 881.
21. McHugh RS, Shevach EM, Margulies DH, Natarajan K. A T cell receptor transgenic model of severe, spontaneous organ-specific autoimmunity. Eur J Immunol 2001 31 : 2094 2103.
22. McHugh RS, Shevach EM. Cutting edge: depletion of CD4+CD25+ regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease. J Immunol 2002 168 : 5979 5983.
23. Pekarek LA, Starr BA, Toledano AY, Schreiber H. Inhibition of tumor growth by elimination of granulocytes. J Exp Med 1995 181 : 435 440.
24. Seung LP, Rowley DA, Dubey P, Schreiber H. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci USA 1995 92 : 6254 6258.
25. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004 4 : 941 952.
26. Bronte V, Zanovello P. Regulation of immune responses by l-arginine metabolism. Nat Rev Immunol 2005 5 : 641 654.
27. McHugh RS, Shevach EM, Margulies DH, Natarajan K. A T cell receptor transgenic model of severe, spontaneous organ-specific autoimmunity. Eur J Immunol 2001 31 : 2094 2103.
28. McHugh RS, Shevach EM. Cutting edge: depletion of CD4+CD25+ regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease. J Immunol 2002 168 : 5979 5983.
29. Young MR, Newby M, Wepsic HT. Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res 1987 47 : 100 105.
30. Zarour H, et al. The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pmel17/gp100. J Invest Dermatol 1996 107 : 63 67.
31. Almand B, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000 6 : 1755 1766.
32. Almand B, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001 166 : 678 689.
33. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004 4 : 762 774.
34. Munn DH, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005 22 : 633 642.
35. Lee GK, Park HJ, Macleod M, Chandler P, Munn DH, Mellor AL. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology 2002 107 : 452 460.
36. Ghosh P, et al. Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J Natl Cancer Inst 1995 87 : 1478 1483.
37. Li X, et al. T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA-binding activity: a preliminary report. Cancer Res 1994 54 : 5424 5429.
38. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992 258 : 1795 1798.
39. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992 258 : 1795 1798.
40. Finke JH, et al. Loss of T-cell receptor zeta chain and p56 lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993 53 : 5613 5616.
41. Kono K, et al. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res 1996 2 : 1825 1828.
42. Zea AH, et al. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1995 1 : 1327 1335.
43. Nakagomi H, et al. Decreased expression of the signal-transducing zeta chains in tumor- infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993 53 : 5610 5612.
44. Nakagomi H, et al. Decreased expression of the signal-transducing zeta chains in tumor- infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993 53 : 5610 5612.
45. Kuss I, Saito T, Johnson JT, Whiteside TL. Clinical significance of decreased zeta chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res 1999 5 : 329 334.
46. Otsuji M, Kimura Y, Aoe T, Okamoto Y, Saito T. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T- cell responses. Proc Natl Acad Sci USA 1996 93 : 13119 13124.
47. Kono K, et al. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res 1996 2 : 1825 1828.
48. Kono K, et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity. Eur J Immunol 1996 26 : 1308 1313.
49. Corsi MM, Maes HH, Wasserman K, Fulgenzi A, Gaja G, Ferrero ME. Protection by l-2-oxothiazolidine-4-carboxylic acid of hydrogen peroxide-induced CD3zeta and CD16zeta chain down-regulation in human peripheral blood lymphocytes and lymphokine-activated killer cells. Biochem Pharmacol 1998 56 : 657 662.
50. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 2001 61 : 4756 4760.
51. Rabinowich H, Reichert TE, Kashii Y, Gastman BR, Bell MC, Whiteside TL. Lymphocyte apoptosis induced by Fas li. J Clin Invest 1998 101 : 2579 2588.
52. Uzzo RG, et al. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res 1999 5 : 1219 1229.
53. Bronstein-Sitton N, et al. Sustained exposure to bacterial antigen induces interferon-gamma-dependent T cell receptor zeta down-regulation and impaired T cell function. Nat Immunol 2003 4 : 957 964.
54. Zea AH, et al. Changes in expression of signal transduction proteins in T lymphocytes of patients with leprosy. Infect Immun 1998 66 : 499 504.
55. Zea AH, et al. Decreased expression of CD3zeta and nuclear transcription factor kappa B in patients with pulmonary tuberculosis: potential mechanisms and reversibility with treatment. J Infect Dis 2006 194 : 1385 1393.
56. Makarenkova VP, Bansal V, Matta BM, Perez LA, Ochoa JB. CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J Immunol 2006 176 : 2085 2094.
57. Carraway MS, Piantadosi CA, Jenkinson CP, Huang YC. Differential expression of arginase and iNOS in the lung in sepsis. Exp Lung Res 1998 24 : 253 268.
58. Kirk SJ, Regan MC, Wasserkrug HL, Sodeyama M, Barbul A. Arginine enhances T-cell responses in athymic nude mice. J Parenter Enteral Nutr 1992 16 : 429 432.
59. Ochoa JB, et al. Trauma increases extrahepatic arginase activity. Surgery 2000 127 : 419 426.
60. Ochoa JB, Strange J, Kearney P, Gellin G, Endean E, Fitzpatrick E. Effects of l-arginine on the proliferation of T lymphocyte subpopulations. JPEN J Parenter Enteral Nutr 2001 25 : 23 29.
61. Barbul A, Rettura G, Levenson SM, Seifter E. Arginine: a thymotropic and wound-healing promoting agent. Surg Forum 1977 28 : 101 103.
62. Albina JE, Caldwell MD, Henry WL Jr., Mills CD. Regulation of macrophage functions by l-arginine. J Exp Med 1989 169 : 1021 1029.
63. Barbul A. Arginine and immune function. Nutrition 1990 6 : 53 58.
64. Taheri F, et al. l-Arginine regulates the expression of the T-cell receptor zeta chain (CD3zeta) in Jurkat cells. Clin Cancer Res 2001 7 : 958s 965s.
65. Brosnan ME, Brosnan JT. Renal arginine metabolism. J Nutr 2004 134 : 2791S 2795S.
66. Nieves C Jr., Langkamp-Henken B. Arginine and immunity: a unique perspective. Biomed Pharmacother 2002 56 : 471 482.
67. Closs EI, Simon A, Vekony N, Rotmann A. Plasma membrane transporters for arginine. J Nutr 2004 134 : 2752S 2759S.
68. Amber IJ, Hibbs JB Jr., Parker CJ, Johnson BB, Taintor RR, Vavrin Z. Activated macrophage conditioned medium: identification of the soluble factors inducing cytotoxicity and the l-arginine dependent effector mechanism. J Leukoc Biol 1991 49 : 610 620.
69. Hibbs JB Jr., Taintor RR, Vavrin Z. Macrophage cytotoxicity: role for l-arginine deiminase and imino nitrogen oxidation to nitrite. Science 1987 235 : 473 476.
70. Morris SM Jr. Regulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr 2002 22 : 87 105.
71. Iyo AH, Zhu MY, Ordway GA, Regunathan S. Expression of arginine decarboxylase in brain regions and neuronal cells. J Neurochem 2006 96 : 1042 1050.
72. Zhu MY, Iyo A, Piletz JE, Regunathan S. Expression of human arginine decarboxylase, the biosynthetic enzyme for agmatine. Biochim Biophys Acta 2004 1670 : 156 164.
73. Cullen ME, et al. Myocardial expression of the arginine:glycine amidinotransferase gene is elevated in heart failure and normalized after recovery: potential implications for local creatine synthesis. Circulation 2006 114 : I16 I20.
74. Item CB, et al. Arginine:glycine amidinotransferase deficiency: the third inborn error of creatine metabolism in humans. Am J Hum Genet 2001 69 : 1127 1133.
75. Hesse M, et al. Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of l-arginine metabolism. J Immunol 2001 167 : 6533 6544.
76. Munder M, Eichmann K, Moran JM, Centeno F, Soler G, Modolell M. Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol 1999 163 : 3771 3777.
77. Munder M, Eichmann K, Modolell M. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol 1998 160 : 5347 5354.
78. Rutschman R, Lang R, Hesse M, Ihle JN, Wynn TA, Murray PJ. Cutting edge: Stat6-dependent substrate depletion regulates nitric oxide production. J Immunol 2001 166 : 2173 2177.
79. Boutard V, Havouis R, Fouqueray B, Philippe C, Moulinoux JP, Baud L. Transforming growth factor-beta stimulates arginase activity in macrophages. Implications for the regulation of macrophage cytotoxicity. J Immunol 1995 155 : 2077 2084.
80. Rodriguez PC, et al. l-arginine consumption by macrophages modulates the expression of CD3zeta chain in T lymphocytes. J Immunol 2003 171 : 1232 1239.
81. Chicoine LG, Paffett ML, Young TL, Nelin LD. Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells. Am J Physiol Lung Cell Mol Physiol 2004 287 : L60 L68.
82. Zhang C, et al. Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension 2004 44 : 935 943.
83. Lee J, Ryu H, Ferrante RJ, Morris SM Jr., Ratan RR. Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. Proc Natl Acad Sci USA 2003 100 : 4843 4848.
84. Santhanam L, et al. Inducible NO Synthase dependent S-nitrosylation and activation of arginase1 contribute to age-related endothelial dysfunction. Circ Res 2007 101 : 692 702.
85. Deignan JL, et al. Ornithine deficiency in the arginase double knockout mouse. Mol Genet Metab 2006 89 : 87 96.
86. Iyer RK, et al. Mouse model for human arginase deficiency. Mol Cell Biol 2002 22 : 4491 4498.
87. Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, Ochoa AC. Regulation of T cell receptor CD3 zeta chain expression by l-arginine. J Biol Chem 2002 277 : 21123 21129.
88. Zea AH, et al. l-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes. Cell Immunol 2004 232 : 21 31.
89. Rodriguez PC, Quiceno DG, Ochoa AC. l-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 2007 109 : 1568 1573.
90. Kato JY. Control of G1 progression by D-type cyclins: key event for cell proliferation. Leukemia 1997 11 (Suppl 3) : 347 351.
91. Ekholm SV, Reed SI. Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 2000 12 : 676 684.
92. Sicinska E, et al. Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell 2003 4 : 451 461.
93. Yaman I, et al. Nutritional control of mRNA stability is mediated by a conserved AU-rich element that binds the cytoplasmic shuttling protein HuR. J Biol Chem 2002 277 : 41539 41546.
94. Yaman I, et al. Nutritional control of mRNA stability is mediated by a conserved AU-rich element that binds the cytoplasmic shuttling protein HuR. J Biol Chem 2002 277 : 41539 41546.
95. Chang CI, Liao JC, Kuo L. Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res 2001 61 : 1100 1106.
96. Suer GS, Yoruk Y, Cakir E, Yorulmaz F, Gulen S. Arginase and ornithine, as markers in human non-small cell lung carcinoma. Cancer Biochem Biophys 1999 17 : 125 131.
97. Singh R, Pervin S, Karimi A, Cederbaum S, Chaudhuri G. Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-l- arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. Cancer Res 2000 60 : 3305 3312.
98. Rodriguez PC, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004 64 : 5839 5849.
99. Gabrilovich DI, et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007 67 : 425.
100. Bronte V, et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000 96 : 3838 3846.
101. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004 172 : 989 999.
102. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 2005 174 : 636 645.
103. Bronte V, et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000 96 : 3838 3846.
104. Seung LP, Rowley DA, Dubey P, Schreiber H. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci USA 1995 92 : 6254 6258.
105. Pekarek LA, Starr BA, Toledano AY, Schreiber H. Inhibition of tumor growth by elimination of granulocytes. J Exp Med 1995 181 : 435 440.
106. Holda JH, Maier T, Claman HN. Murine graft-versus-host disease across minor barriers: immunosuppressive aspects of natural suppressor cells. Immunol Rev 1985 88 : 87 105.
107. Rodriguez PC, Zea AH, Ochoa AC. Mechanisms of tumor evasion from the immune response. Cancer Chemother Biol Response Modif 2003 21 : 351 364.
108. Rodriguez PC, Ochoa AC. T cell dysfunction in cancer: role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress. Semin Cancer Biol 2005 105 : 2549 2556.
109. Bronte V, et al. IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice. J Immunol 2003 170 : 270 278.
110. Kusmartsev S, Gabrilovich DI. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol 2005 174 : 4880 4891.
111. Nagaraj S, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007 13 : 828 835.
112. Van Ginderachter JA, et al. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood 2006 108 : 525 535.
113. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 2001 166 : 5398 5406.
114. Sinha P, Clements VK, Ostrand-Rosenberg S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res 2005 65 : 11743 11751.
115. Gallina G, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+T cells. J Clin Invest 2006 116 : 2777 2790.
116. Huang B, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006 66 : 1123 1131.
117. Pan PY, et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid derived suppressor cell development by blockade of SCF function. Blood 2008 111 : 219 228.
118. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007 179 : 977 983.
119. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007 117 : 1155 1166.
120. Zea AH, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005 65 : 3044 3048.
121. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 2001 61 : 4756 4760.
122. Rodgers S, Rees RC, Hancock BW. Changes in the phenotypic characteristics of eosinophils from patients receiving recombinant human interleukin-2 (rhIL-2) therapy. Br J Haematol 1994 86 : 746 753.
123. Munder M, et al. Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. Blood 2005 105 : 2549 2556.
124. Jacobsen LC, Theilgaard-Monch K, Christensen EI, Borregaard N. Arginase 1 is expressed in myelocytes/metamyelocytes and localized in gelatinase granules of human neutrophils. Blood 2007 109 : 3084 3087.
125. Kropf P, et al. Arginase activity mediates reversible T cell hyporesponsiveness in human pregnancy. Eur J Immunol 2007 37 : 935 945.
126. Munder M, et al. Suppression of T-cell functions by human granulocyte arginase. Blood 2006 108 : 1627 1634.
127. Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 2001 23 : 263 272.
128. Gabrilovich D, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998 92 : 4150 4166.
129. Oyama T, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 1998 160 : 1224 1232.
130. Kusmartsev S, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 2003 63 : 4441 4449.
131. Solheim JC, et al. Spleen but not tumor infiltration by dendritic and T cells is increased by intravenous adenovirus-Flt3 ligand injection. Cancer Gene Ther 2007 14 : 364 371.
132. Rodriguez PC, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 2005 202 : 931 939.
133. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007 67 : 4507 4513.
134. Talmadge JE, Hood KC, Zobel LC, Shafer LR, Coles M, Toth B. Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. Int Immunopharmacol 2007 7 : 140 151.
135. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003 3 : 721 732.
136. De SC, et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci USA 2005 102 : 4185 4190.
137. Serafini P, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006 203 : 2691 2702.